Trial Profile
A retrospective study of GBS events secondary to ICI treatments in patients based on the Food and Drug Administration Adverse Event Reporting System (FAERS).
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 06 Jul 2021
Price :
$35
*
At a glance
- Drugs Atezolizumab (Primary) ; Avelumab (Primary) ; Durvalumab (Primary) ; Ipilimumab (Primary) ; Ipilimumab/nivolumab (Primary) ; Nivolumab (Primary) ; Pembrolizumab (Primary)
- Indications Guillain-Barre syndrome
- Focus Adverse reactions
- 06 Jul 2021 New trial record
- 01 Jun 2021 Results published in the Journal of Neurology